Clinical Trial Update: Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy [Phase 1]

View source ↗

Summary

Phase 1 safety study of CLT-008 human myeloid progenitor cells after cord blood transplantation for hematologic malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Plasma Cell Neoplasm

Drugs mentioned

• Human Myeloid Progenitor Cells (CLT-008)

Snippet

Sponsor: Cellerant Therapeutics | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED